Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Vera Therapeutics, Inc. VERA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
57/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$77.60
+74.9%

Vera Therapeutics, Inc. (VERA) is a Biotechnology company in the Healthcare sector, currently trading at $44.36. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Analyst consensus target is VERA = $78 (+74.9% upside).

Valuation: VERA trades at a trailing Price-to-Earnings (P/E) of -8.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.22.

Net income is $300M (loss), growing at -54.4%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $77M against $605M equity (Debt-to-Equity (D/E) ratio 0.13, conservative). Current ratio is 13.64 (strong liquidity). Debt-to-assets is 10.5%. Total assets: $735M.

Analyst outlook: 13 / 14 analysts rate VERA as buy (93%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 58/100 (Partial), Future 100/100 (Pass), Income ?/100 (Fail).

$77.60
▲ 74.93% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Vera Therapeutics, Inc., the average price target is $77.60, with a high forecast of $97.00, and a low forecast of $33.00.
Highest Price Target
$97.00
Average Price Target
$77.60
Lowest Price Target
$33.00

VERA SharesGrow Score Overview

68/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 58/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VERA

✓
VALUE Pass
100/100
VERA trades at a trailing Price-to-Earnings (P/E) of -8.6 (S&P 500 average ~25). Forward PEG 0.22 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.66. Analyst consensus target is $78, implying +75.8% from the current price $44. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
VERA: -100%/yr revenue is, -54.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet VERA: Debt-to-Equity (D/E) ratio 0.13 (conservative), Current ratio is 13.64 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
58/100
VERA: Gross margin is 100% (+0 pp trend), $3B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 13 / 14 analysts rate VERA as buy (93%). Analyst consensus target is $78 (+75.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range18.53-56.05
Volume1.23M
Avg Volume (30D)1.42M
Market Cap$3.17B
Beta (1Y)1.17
Share Statistics
EPS (TTM)-4.66
Shares Outstanding$64.23M
IPO Date2021-05-14
Employees152
CEOMarshall W. Fordyce
Financial Highlights & Ratios
Gross Profit$-468K
EBITDA$-291.62M
Net Income$-299.62M
Operating Income$-315.47M
Total Cash$714.59M
Total Debt$77.31M
Net Debt$-277.42M
Total Assets$734.73M
Price / Earnings (P/E)-9.5
Analyst Forecast
1Y Price Target$90.00
Target High$97.00
Target Low$33.00
Upside+102.9%
Rating ConsensusBuy
Analysts Covering14
Buy 93% Hold 7% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS92337R1014

Price Chart

Track all markets on TradingView
VERA
Vera Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
18.53 52WK RANGE 56.05

People Also View

CYTK
CYTK
Cytokinetics, Incorporated
$66.35
-0.55%
 COGT
COGT
Cogent Biosciences, Inc.
$36.49
-0.08%
 TVTX
TVTX
Travere Therapeutics, Inc.
$42.13
+37.23%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 TARS
TARS
Tarsus Pharmaceuticals, Inc.
$73.81
+1.60%
 DICE
DICE
DICE Therapeutics, Inc.
$47.55
+0.06%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 TYRA
TYRA
Tyra Biosciences, Inc.
$35.27
-0.98%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message